Liquid biopsies for cancer recurrence create a new kind of patient-in-waiting

Scientific advances such as the Signatera liquid biopsy test may have unintended consequences for patients and caregivers.

October 31, 2023 Check out STAT+

Sponsored By

Courtesy Mara Buchbinder Opinion: Liquid biopsy for cancer recurrence creates a new kind of patient-in-waiting When a test to predict my husband's cancer recurrence came back positive, there was only one thing we could do: wait. By Mara Buchbinder STAT+ | ARPA-H head Renee Wegrzyn on the agency's new Cambridge hub and plans for cancer research Renee Wegrzyn, director of ARPA-H, visited Cambridge for the launch of the agency's new Investor Catalyst Hub. By Theresa Gaffney Opinion: The pink ribbon of breast cancer awareness needs a splash of blue for men Men get breast cancer, too. The iconic pink awareness ribbon needs a dash of blue to reflect them. By Vivian Kobusingye Birchall

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser